FDA controversially approves potent opioid up to ten times stronger than fentanyl
November 6, 2018Sales and Marketing Dsuvia, FDA, US, fentanyl, opioid crisis, opioids, pharma
Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five …
Aurobindo pharma initiate recall of blood pressure drug Ibesartan
November 6, 2018Manufacturing and Production, Research and Development Aurobindo Pharma, FDA, heart drug, ibesartan, recall
Indian pharma firm Aurobindo Pharma Ltd has initiated a voluntary recall of 22 batches of blood pressure drug Ibesartan, due …
76% of patients no longer experience PTSD a year after MDMA-assisted psychotherapy
November 6, 2018Manufacturing and Production, Research and Development MDMA, PTSD, mental health, psychotherapy, research
Promising phase II results suggest that MDMA-assisted psychotherapy may be an “innovative, efficacious treatment for posttraumatic stress disorder,” according to …
HIV drug reduces viral load by 99% within 4 weeks
November 6, 2018Manufacturing and Production, Research and Development
HIV-drug Gammora may eliminate 99% of the HIV virus within four weeks of treatment, according to the results of a …
GSK’s anti-seizure drug shows promise in early depression study
November 2, 2018Medical Communications, Research and Development GSK, GlaxoSmithKline, Potiga, depression, pharma
Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications …
Top Ten most popular articles on Pharmafile.com this week!
November 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10
Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …
Committee advises against FDA approval of Alkermes’ novel depression drug
November 2, 2018Medical Communications, Sales and Marketing Alkermes, FDA, depression, pharma
Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs Advisory Committee …
Novo Nordisk cuts 1300 jobs in the midst of Trump’s pricing pressures and depreciation of US dollar
November 2, 2018Medical Communications Jobs, Novo Nordisk, Trump, pressure, pricing, revenue
Danish multinational Novo Nordisk has said that they will have cut 1,300 employees by the end of 2018. The decision …
GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States
November 2, 2018Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis
GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …
Galectin-3: The protein paving new treatment avenues
November 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Galectin-3, Galectins, breast cancer, diabetes, heart disease, pharma
Matthew Blakeley, LADI-III Beamline Scientist at Institut Laue-Langevin (ILL) and Derek Logan, Associate Professor in Structural Biology at Lund University, …
Sanofi teams up with Denali in $1.125bn neurological and inflammatory development deal
November 1, 2018Research and Development, Sales and Marketing Denali Therapeutics, Sanofi, pharma
Sanofi has sealed the deal with Denali Therapeutics to leverage the latter’s small molecule candidates in the development of new …
Medical Marijuana to be legalised in Thailand and Malaysia as drug becomes available on prescription in UK
November 1, 2018Business Services, Medical Communications Medical marijuana, UK, cannabis, malaysia, thailand
Thailand’s public health ministry is working to make medical marijuana legal by next month. The shift is expected to come …
Novartis cuts 20% of research projects
November 1, 2018Business Services, Research and Development Business, Novartis, gene therapy, infectious diseases, research
Swiss multinational Novartis has cut a fifth of its research projects, as it abandons 90 of its 430 drug development …
MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer
November 1, 2018Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …
Parents should ignore anti-vaccine “social media fake news”, according to England’s medical chief
November 1, 2018Medical Communications England, MMR, Vaccine, anti-vaccine, fake news
England’s Chief Medical Officer Dame Sally Davies has said that the MMR vaccine is “a safe vaccination” as she encouraged …
Metropolitan Police charge ITH Pharma over IV feed-linked baby deaths
October 31, 2018Research and Development ITH Pharma, Metropolitan Police, NHS, pharma
An investigation into the deaths and illnesses of several babies at a number of UK hospitals has prompted London’s Metropolitan …
AstraZeneca flogs two drug licenses in $922 million deal
October 31, 2018Research and Development, Sales and Marketing AstraZeneca, pharma
AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional …
Common diabetes drug can protect against age-related macular degeneration, research shows
October 31, 2018Research and Development age-related macular degeneration, diabetes, eye, metformin, pharma
A Taiwanese research team has demonstrated a link between the use of the common diabetes medication metformin and significantly lower …
J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk
October 31, 2018Research and Development, Sales and Marketing FDA, J&J, JJ, invokana, pharma
The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of …
NICE turns down Sanofi’s Caprelsa for rare thyroid cancer
October 31, 2018Research and Development, Sales and Marketing Cancer, Caprelsa, NHS, NICE, Sanofi, UK, medullary thyroid cancer, pharma
NICE has announced its recommendation to reject Sanofi’s Caprelsa (vandetanib) for use on the NHS in the treatment of medullary …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
